X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (22047) 22047
Newsletter (624) 624
Newspaper Article (351) 351
Book Chapter (48) 48
Dissertation (29) 29
Magazine Article (22) 22
Publication (19) 19
Transcript (14) 14
Conference Proceeding (5) 5
Streaming Video (5) 5
Book Review (2) 2
Government Document (1) 1
Journal / eJournal (1) 1
Reference (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15644) 15644
carboplatin (14268) 14268
oncology (12115) 12115
female (11437) 11437
chemotherapy (9500) 9500
middle aged (8337) 8337
antineoplastic combined chemotherapy protocols - therapeutic use (7885) 7885
male (7849) 7849
carboplatin - administration & dosage (7611) 7611
aged (7327) 7327
cancer (6774) 6774
adult (6592) 6592
cisplatin (5919) 5919
paclitaxel (4623) 4623
treatment outcome (4047) 4047
lung neoplasms - drug therapy (3991) 3991
paclitaxel - administration & dosage (3362) 3362
antineoplastic combined chemotherapy protocols - adverse effects (3144) 3144
carcinoma, non-small-cell lung - drug therapy (2984) 2984
neoplasm staging (2982) 2982
cisplatin - administration & dosage (2720) 2720
care and treatment (2692) 2692
ovarian neoplasms - drug therapy (2686) 2686
carcinoma (2509) 2509
antineoplastic agents - therapeutic use (2499) 2499
carboplatin - adverse effects (2477) 2477
combined modality therapy (2412) 2412
ovarian cancer (2409) 2409
carboplatin - therapeutic use (2350) 2350
aged, 80 and over (2343) 2343
research (2251) 2251
prognosis (2245) 2245
survival (2143) 2143
disease-free survival (2123) 2123
lung neoplasms - pathology (2116) 2116
trial (2100) 2100
survival rate (2050) 2050
retrospective studies (2024) 2024
therapy (1964) 1964
tumors (1827) 1827
animals (1807) 1807
radiotherapy (1789) 1789
etoposide - administration & dosage (1778) 1778
drug administration schedule (1757) 1757
lung cancer (1739) 1739
survival analysis (1705) 1705
antineoplastic combined chemotherapy protocols - administration & dosage (1697) 1697
pharmacology & pharmacy (1688) 1688
antineoplastic agents - administration & dosage (1581) 1581
gemcitabine (1562) 1562
combination (1560) 1560
carcinoma, non-small-cell lung - pathology (1529) 1529
etoposide (1511) 1511
obstetrics & gynecology (1503) 1503
analysis (1417) 1417
lung cancer, non-small cell (1400) 1400
surgery (1362) 1362
antineoplastic agents (1350) 1350
hematology, oncology and palliative medicine (1334) 1334
follow-up studies (1331) 1331
ovarian neoplasms - pathology (1329) 1329
metastasis (1327) 1327
bevacizumab (1319) 1319
cancer therapies (1304) 1304
dose-response relationship, drug (1274) 1274
toxicity (1273) 1273
phase-ii (1267) 1267
patients (1256) 1256
docetaxel (1248) 1248
antineoplastic agents - adverse effects (1244) 1244
medicine & public health (1223) 1223
platinum (1212) 1212
deoxycytidine - analogs & derivatives (1200) 1200
antimitotic agents (1198) 1198
lung neoplasms - mortality (1192) 1192
respiratory system (1187) 1187
health aspects (1184) 1184
drug therapy (1159) 1159
cyclophosphamide (1156) 1156
adolescent (1131) 1131
phase-iii trial (1117) 1117
chemotherapy, adjuvant (1105) 1105
non-small cell lung cancer (1098) 1098
oncology, experimental (1067) 1067
clinical trials (1044) 1044
deoxycytidine - administration & dosage (1008) 1008
antineoplastic agents - pharmacology (971) 971
carcinoma, non-small-cell lung - mortality (948) 948
hematology (945) 945
carboplatin - pharmacology (940) 940
cisplatin - therapeutic use (939) 939
paclitaxel - adverse effects (932) 932
cyclophosphamide - administration & dosage (912) 912
child (886) 886
phase-ii trial (874) 874
prospective studies (872) 872
mice (871) 871
time factors (871) 871
breast cancer (861) 861
randomized-trial (855) 855
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (21814) 21814
Japanese (669) 669
French (344) 344
German (299) 299
Chinese (206) 206
Spanish (85) 85
Italian (56) 56
Russian (39) 39
Korean (33) 33
Portuguese (31) 31
Polish (27) 27
Hungarian (16) 16
Czech (13) 13
Dutch (12) 12
Turkish (7) 7
Serbian (4) 4
Lithuanian (3) 3
Romanian (3) 3
Bulgarian (2) 2
Danish (2) 2
Finnish (2) 2
Hebrew (2) 2
Persian (2) 2
Slovak (2) 2
Arabic (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2014, Volume 371, Issue 23, pp. 2167 - 2177
The ALK inhibitor crizotinib as first-line therapy was associated with a significantly better response rate, longer progression-free survival, and greater... 
CRITERIA | MEDICINE, GENERAL & INTERNAL | GEFITINIB | THERAPY | CISPLATIN | ADENOCARCINOMA | PHASE-III | KINASE | ANAPLASTIC LYMPHOMA | QLQ-C30 | PLUS | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Cisplatin - administration & dosage | Pyridines - adverse effects | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carboplatin - administration & dosage | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Glutamates - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Adenocarcinoma - mortality | Guanine - administration & dosage | Crizotinib | Treatment outcome | Chemotherapy | Usage | Care and treatment | Lung cancer | Analysis | Dosage and administration | Comparative analysis | Risk factors | Cancer | Appetite | Edema | Inhibitor drugs | Intravenous administration | Biomedical research | Diarrhea | Non-small cell lung carcinoma | Fatigue | Nausea | Metastasis | Patients | Cisplatin | Quality of life | Lungs | Platinum | Vomiting | Comparative studies | Carboplatin
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9796, pp. 1079 - 1088
Summary Background Platinum-based doublet chemotherapy is recommended to treat advanced non-small-cell lung cancer (NSCLC) in fit, non-elderly adults, but... 
Internal Medicine | SURVIVAL | MEDICINE, GENERAL & INTERNAL | MANAGEMENT | INTERNATIONAL-SOCIETY | GERIATRIC ASSESSMENT | UNDERREPRESENTATION | OLDER | OUTCOMES | COMBINATION | AGE | COMORBIDITY | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Carboplatin - adverse effects | Carcinoma, Squamous Cell - mortality | Vinblastine - analogs & derivatives | Antineoplastic Agents - adverse effects | Aged, 80 and over | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Survival Rate | Adenocarcinoma - drug therapy | Carcinoma, Non-Small-Cell Lung - mortality | Carcinoma, Squamous Cell - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Deoxycytidine - analogs & derivatives | Adenocarcinoma - mortality | Clinical trials | Chemotherapy | Radiation therapy | Cancer therapies | Adenocarcinoma | Vinblastine | Carcinoma, Non-Small-Cell Lung | Antineoplastic Agents | Antineoplastic Combined Chemotherapy Protocols | Lung Neoplasms | Carcinoma, Squamous Cell | Life Sciences | Deoxycytidine | Paclitaxel | Carboplatin | Cancer
Journal Article
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2016, Volume 34, Issue 25, pp. 2969 - 2979
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2011, Volume 365, Issue 26, pp. 2484 - 2496
The addition of bevacizumab to chemotherapy (15 mg/kg for six cycles) followed by extended therapy with bevacizumab every 3 weeks for a total of 15 months of... 
CARBOPLATIN-PACLITAXEL | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | INTERGROUP TRIAL | GYNECOLOGIC-ONCOLOGY-GROUP | SOLID TUMORS | ANGIOGENESIS | CYCLOPHOSPHAMIDE | EXPRESSION | INTRAPERITONEAL CISPLATIN | III TRIAL | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Combined Modality Therapy | Ovarian Neoplasms - mortality | Neoplasms, Glandular and Epithelial - surgery | Bevacizumab | Disease-Free Survival | Neoplasms, Glandular and Epithelial - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoplasms, Glandular and Epithelial - drug therapy | Survival Analysis | Angiogenesis Inhibitors - therapeutic use | Carcinoma, Ovarian Epithelial | Quality of Life | Female | Paclitaxel - administration & dosage | Angiogenesis Inhibitors - adverse effects | Ovarian Neoplasms - drug therapy | Ovarian Neoplasms - surgery | Drugs | Dose-response relationship (Biochemistry) | Product/Service Evaluations | Drug therapy | Ovarian cancer | Angiogenesis | Chemotherapy | Womens health | Body weight | Paclitaxel | Clinical trials | Carboplatin | Vascular endothelial growth factor | Survival | Cancer | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 1, pp. 23 - 34
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2015, Volume 33, Issue 17, pp. 1902 - 1909
Journal Article